-
Mashup Score: 0CRT Plus Chemo Did Not Improve RFS in Resected Gallbladder Cancer - 17 hour(s) ago
Results from the ACCELERATE trial did not improve relapse-free survival when chemoradiation was added to chemotherapy for patients with resected gallbladder cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
The NeoCaCRT trial found that SCRT followed by cadonilimab and mFOLFOX6 elicited a pCR of 37.0%, meeting its primary end point for patients with locally advanced rectal cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
At the October 20, 2024, data cutoff, with a median follow-up of 9.7 months, the pCR rate was 37.0% (95% CI, 19.4%-57.6%); the clinical mPR was 55.6% (95% CI, 35.3%-74.5%). #GI25 #gicsm | @ASCO https://t.co/PeuCURyHoO
-
-
Mashup Score: 0Neoadjuvant Pembrolizumab Enhances Response in dMMR Colon Cancer - 20 hour(s) ago
A pCR rate of 44% was observed when neoadjuvant pembrolizumab was given to patients with dMMR colon cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
A pCR was noted in 44% (95% CI, 33%-55%) of patients and a mPR in 57% (95% CI, 46%-68%). For stage I or II, the pCR rate was 61% and for stage III it was 33%. #GI25 #gicsm | @ASCO https://t.co/3IpTcKDmf6
-
-
Mashup Score: 0
No differences in oncologic outcomes occurred between mandatory TME or selective WW strategy in rectal cancer responders to neoadjuvant therapy.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
“A selective watch-and-wait strategy is a safe treatment option in patients with a [CR] or [nCR] to TNT. We found no differences in oncologic outcomes based on treatment strategy,” said Hannah Williams, MD. #GI25 #gicsm | @ASCO https://t.co/i2zLlBvINs
-
-
Mashup Score: 0
The results of a real-world study support palliative care integration in patients with advanced early-onset colorectal cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Palliative care involvement in patients with early-onset colorectal cancer may reduce invasive and uncomfortable intervention use, resulting in a subjective improvement in patient end-of-life comfort. #GI25 #gicsm | @ASCO https://t.co/zLbRsX9kKR
-
-
Mashup Score: 1
Patients who received cabozantinib experienced a PFS of 8.5 months vs 5.6 months with placebo, a subgroup analysis from the CABINET trial found.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
“Potential benefit was observed across clinical factors including grade, functional status, [use] concurrent somatostatin analogs, and prior treatment,” said Jonathan Strosberg, MD. #GI25 #gicsm | @ASCO https://t.co/eIEjwYlhnu
-
-
Mashup Score: 1
Results from the phase 3 LAPIS trial showed pamrevlumab/chemotherapy did not improve survival vs placebo/chemotherapy in locally advanced, unresectable pancreatic cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Topline results in the combination arm included a median overall survival of 17.3 months compared with 18.0 months in the placebo arm (HR, 1.08; 95% CI, 0.83-1.41; P = .5487). #GI25 #gicsm | @ASCO https://t.co/T6kqzzS0Sj
-
-
Mashup Score: 3
Additionally, data show a trend towards improved overall survival with TACE plus camrelizumab/rivoceranib in the phase 2 CARES-005 study.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Combining TACE with camrelizumab and rivoceranib elicited a clinically meaningful and statistically significant PFS improvement among patients with unresectable hepatocellular carcinoma. #GI25 #gicsm | @ASCO https://t.co/HKSvKWvX49
-
-
Mashup Score: 1
SHR-1701 plus CAPOX chemotherapy elicited fewer chemo delays and dose reductions and improved AE data vs placebo plus CAPOX in HER2-negative gastric/GEJ cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
SHR-1701 in combination with chemotherapy demonstrated the ability to suppress chemotherapy-associated myelosuppression in patients with HER2-negative gastric/gastroesophageal junction adenocarcinoma. #GI25 #gicsm | @ASCO https://t.co/uxZjiXZHAM
-
-
Mashup Score: 2Call for Papers - 4 month(s) ago
Call for Papers
Source: asco.confex.comCategories: General Medicine News, Partners & KOLsTweet-
📢 Calling all researchers! Time is running out to showcase your study @ the leading multidisciplinary global meeting for GI cancer research. Submit your abstract for #GI25 by 11:59pm ET, Sept 24: https://t.co/lZ2MVgHM1k @SocSurgOnc @ASTRO_org @AGA_Gastro @AmerGastroAssn #gicsm https://t.co/SivfCmEh7P
-
The median survival was 52.7 months. Kaplan Meier estimates for RFS showed an HR of 1.59 (95% CI, 0.83-3.03) and an adjusted HR (aHR) of 1.09 (95% CI, 0.54-2.17). #GI25 #gicsm | @ASCO https://t.co/LHrtXvdEQP